Examkin

Soru

Zorluk: KolayHematology and Oncology

A 55-year-old man who underwent a coronary artery bypass graft surgery five days ago develops acute swelling and pain in his right calf. His platelet count has dropped from 250,000/mm3250,000/\text{mm}^3 postoperatively to 90,000/mm390,000/\text{mm}^3 today. He has been receiving subcutaneous unfractionated heparin for deep vein thrombosis prophylaxis. A venous duplex ultrasound confirms a new right lower extremity deep vein thrombosis. He is clinically suspected of having heparin-induced thrombocytopenia (HIT). Arrange the following pathophysiologic steps in the correct chronological order detailing the development of this patient's condition.

  1. 1Heparin molecules bind to platelet factor 4 (PF4), forming a highly immunogenic neoantigen complex.
  2. 2The patient's immune system generates specific IgG autoantibodies directed against the newly formed complex.
  3. 3The newly formed IgG antibodies bind to the circulating heparin-PF4 complexes.
  4. 4The Fc portion of the IgG antibodies cross-links with Fc-gamma-RIIA receptors on the surface of platelets.
  5. 5Platelets become strongly activated, releasing prothrombotic microparticles and subsequently being consumed.

Cevap

The correct chronological sequence is: 1) Heparin binds to PF4; 2) IgG antibodies are generated against the complex; 3) IgG binds to the heparin-PF4 complex; 4) The immune complex binds to platelet Fc receptors; 5) Platelets activate, cause thrombosis, and are consumed.
Heparin-induced thrombocytopenia (HIT) Type 2 is a prothrombotic, immune-mediated disorder. The sequence begins when exogenous heparin binds to endogenous platelet factor 4 (PF4), forming a highly immunogenic neoantigen. The body responds by creating IgG autoantibodies against this complex. These newly formed IgG antibodies bind to the circulating heparin-PF4 complexes. The Fc portion of these IgG antibodies then binds to and cross-links Fc-gamma-RIIA receptors on the surface of platelets. This intense cross-linking results in widespread platelet activation. Activated platelets release procoagulant microparticles, leading to a severe hypercoagulable state and thrombosis. Concurrently, the activated and antibody-coated platelets are rapidly cleared by the reticuloendothelial system (primarily the spleen), resulting in the characteristic drop in platelet count (thrombocytopenia). Therefore, the paradoxical presentation of thrombosis in the setting of thrombocytopenia is a direct result of this immune-mediated platelet activation and consumption.

Adım Adım Çözüm

1
Identify the underlying diagnosis based on the clinical presentation.
The patient has a drop in platelets >50% and a new thrombosis 5 days after starting heparin, which is classic for Heparin-Induced Thrombocytopenia (HIT) Type 2.
Recognizing the condition is necessary to determine its underlying pathophysiologic mechanism.
2
Determine the initiating molecular event of HIT Type 2.
The sequence begins with the binding of administered heparin to endogenous platelet factor 4 (PF4).
This interaction creates the neoantigen that triggers the immune response.
3
Trace the subsequent immune system response.
The immune system recognizes the neoantigen and produces IgG antibodies, which then bind to the heparin-PF4 complexes.
Antibody formation and binding must occur before cellular activation can take place.
4
Identify how the immune complexes interact with cells.
The IgG-heparin-PF4 complexes bind to Fc-gamma-RIIA receptors on the platelet surface.
This binding bridges the humoral immune response to cellular activation.
5
Determine the final clinical consequences of this cellular interaction.
Platelets become activated (causing thrombosis) and are eventually removed from circulation (causing thrombocytopenia).
This explains the paradoxical presentation of thrombosis in the setting of low platelets.

Anahtar Kavram

Pathophysiology of Heparin-Induced Thrombocytopenia (HIT) Type 2
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru